Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - elotuzumab, quantity: 440 mg - injection, powder for - excipient ingredients: sodium citrate dihydrate; citric acid monohydrate; sucrose; polysorbate 80; water for injections - empliciti (elotuzumab) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - elotuzumab, quantity: 340 mg - injection, powder for - excipient ingredients: sodium citrate dihydrate; citric acid monohydrate; sucrose; polysorbate 80; water for injections - empliciti (elotuzumab) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - sodium ascorbate, quantity: 90 g/l - injection, intravenous infusion - excipient ingredients: water for injections - sodium ascorbate injections are indicated for the treatment of vitamin c deficiency when oral treatment is not feasible

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - carboplatin, quantity: 10 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - carboplatin is indicated in the treatment of ovarian cancer of epithelial origin and in second line therapy after other treatments have failed.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sodium bicarbonate, quantity: 8.4 g - injection, intravenous infusion - excipient ingredients: disodium edetate; water for injections - 1. metabolic acidosis in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis where a rapid increase in plasma total co2 content is crucial. treatment of metabolic acidosis should be concurrent with measures designed to control the cause of the acidosis. 2.urinary alkalinisation in the treatment of certain drug intoxications (ie barbiturates, salicylates, lithium, methyl alcohol) and in the haemolytic reactions requiring alkalinisation of the urine to diminish nephrotoxicity of blood pigments. urinary alkalinisation is also used in methotrexate therapy to prevent nephrotoxicity. 3.severe diarrhoea which is often accompanied by a significant loss of bicarbonate.

Singapor - Ingliż - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - aflibercept - infusion, solution concentrate - 25.0 mg/ml - aflibercept 25.0 mg/ml

Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

bowmed ibisqus ltd - fluconazole - infusion - 2mg/1ml

Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

bowmed ibisqus ltd - fluconazole - infusion - 2mg/1ml

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - bendamustine hydrochloride - powder for concentrate for solution for infusion - 25 milligram(s) - nitrogen mustard analogues; bendamustine - antineoplastic agents, alkylating agents - first-line treatment of chronic lymphocytic leukaemia. indolent non-hodgkin's lymphomas. front line treatment of multiple myeloma

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - bendamustine hydrochloride - powder for concentrate for solution for infusion - 100 milligram(s) - nitrogen mustard analogues; bendamustine - antineoplastic agents, alkylating agents - first-line treatment of chronic lymphocytic leukaemia. indolent non-hodgkin's lymphomas. front line treatment of multiple myeloma.